Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRANSFORM: GSK3915393 in Idiopathic Pulmonary Fibrosis
NCT06317285Phase 2Terminated
- Sponsor
- GSK
- Start
- Apr 2024
- Primary completion
- Oct 2025
- Countries
- 10
01
Overview
A Phase 2 trial of GSK3915393 in idiopathic pulmonary fibrosis (IPF), sponsored by GSK. Started Apr 2024; status: terminated.
02
Drugs
GSK3915393
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT06317285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06317285.